Biomarker Solutions

Pharmaimage Biomarker Solutions Inc. BostonBerlin - Boston: We are pleased to announce that Pharmaimage has opened an additional location in Boston/USA.

Serious adverse events (SAEs) during clinical phase-I studies (first dosing, dose escalation) are rare but can be devastating as exemplified by the recent incident at the clinical research organization (CRO) Biotrial in France or another incident during a trial that was conducted by the CRO Parexel (UK) in 2006.

Pharmaimage (Berlin, Germany) and the Clinical Research Organization (CRO) Hammersmith Medicines Research (HMR) in London (UK) have established a real-time neurophysiological/video monitoring system as part of a new phase-I drug trial.

The FP7 EU-funded BioCog Consortium (Biomarker Development for Postoperative Cognitive Impairment in the Elderly), which includes Pharmaimage GmbH as a major partner, has been selected by the Berlin Institute of Health (BIH) as a „pathfinder study“.

Pharmaimage is happy to announce its participation as a strategic partner of the newly established EU-funded FP7 research consortium: Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog):

© PI-PharmaImage Germany GmbH 2017 | Webdesign: blickpunkt x, Köln